Mankind Pharma’s ₹13,630 Crore Deal to Buy Bharat Serums Gets CCI Approval—A Game-Changer for Indian Healthcare

Mankind Pharma’s plan to acquire Bharat Serums and Vaccines for ₹13,630 crore has been approved by the Competition Commission of India (CCI). The approval was announced by the CCI on Tuesday via a post on X.

Mankind Pharma first shared its intention to acquire Bharat Serums in July. The deal involves buying the entire 100% stake from Advent International, a private equity firm, for an enterprise value of ₹13,630 crore.

Fundraising Plans

On September 30, Mankind Pharma also revealed its plan to raise up to ₹10,000 crore through non-convertible debentures and commercial papers. The company’s board approved raising up to ₹5,000 crore via non-convertible debentures in 3-4 separate series with maturities of up to 48 months.

Regulatory Approval

In India, deals that exceed a certain financial threshold need approval from the CCI to ensure fair competition and prevent monopolistic practices. The approval of this acquisition highlights the importance of such checks for large-scale mergers and acquisitions.

A Key Milestone for Mankind Pharma

Rajeev Juneja, Vice-Chairman and Managing Director of Mankind Pharma, described the acquisition of Bharat Serums and Vaccines (BSV) as a significant step forward for the company. He emphasized that this deal strengthens Mankind’s position as a leader in women’s health and fertility care in India.

About the Companies

Mankind Pharma is one of the largest pharmaceutical companies in India. It focuses on developing, manufacturing, and marketing a wide variety of finished dosage formulations. The company also manufactures and sells active pharmaceutical ingredients (APIs) and pharmaceutical intermediates.

Bharat Serums and Vaccines (BSV) is a key player in the biopharmaceutical industry. It specializes in research, development, and production of pharmaceutical formulations, APIs, food supplements, and health products. BSV is especially strong in the areas of women’s healthcare, assisted reproductive treatments, critical care, and emergency medicine.